- Global Pharma News & Resources

Stability Screening Meets Tetravalent Bispecifics In Next Generation Collaboration

Leatherhead, UK - 1st July 2021 - Life Science Newswire - Protein Stable and F-star Therapeutics have entered into a collaboration to explore the benefits of the high throughput SUPR-CM platform for early development, lead selection, formulation development and stability prediction. Jon Armer, Formulation Lead Senior Scientist at F-star commented: “At F-star, we are developing next generation tetravalent bispecifics for cancer immunotherapy which we create in a unique manner to maintain the natural antibody format. It is hoped that we will be able to leverage the many advantages of the SUPR-CM platform to allow us to better understand our molecules at an earlier stage improving the chances of success for the development of our programs, whilst shrinking timelines and resource requirements”.

The ability to predict the stability of molecules in development is an extremely important tool for scientists. Chemical melt methodology (leading to the transition point, Cm) is increasingly being adopted as a more representative predictor of stability; the ability of a molecule to re-fold following denaturation has been strongly linked to its likelihood to degrade under real-world stability conditions. However, as chemical melts require multiple reagents to be prepared including the denaturant, stabilising agents under evaluation and samples, it is laborious, is prone to pipetting errors, extensive measurement times and poor repeatability. Furthermore, transfers to vials or capillaries for analysis adds extra unnecessary steps and can be expensive, especially with proprietary consumables. This means that many scientists who could adopt the method actively avoided doing so. In time the value that Cm profiling has offered to drug development has waned due to the complexity of the setup. This hurdle, despite the clear data-rich information it offers, limits its use in a practical sense. The SUPR-CM offers a chemical melt solution that solves all of these issues, and allows researchers to readily and easily adopt the method to complement DSC or other thermal denaturation methods or to generate data at stages of the project where alternative methods cannot be used. To learn more about F-star or the SUPR-CM follow the links below:

About Protein Stable:

Protein Stable applies innovation in protein characterisation to help scientists and researchers across academia and the biotechnology industry. Our focus is on high throughput, low volume methods for protein characterisation for increased productivity, without compromise to data quality.

Protein Stable is a joint venture between Applied Photophysics (APP) and Fluorescence Innovations (FI). For more information visit: and follow us on LinkedIn.

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumorimmune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit and follow us on LinkedIn and Twitter.

Editor Details

Last Updated: 01-Jul-2021